Replies to post #13288 on GT Biopharma Inc (GTBP)

[BullsOnFire]

OXS-3550 TriKE has been proven to superior to OXS-1550 in in vivo studies, so I don't expect OXS-1550 to pass Phase II trials, however OXS-3550 TriKE most likely will. As it has been proven to be more effective than Rituxan in killing cancer cells.